• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in Three Major Racial and Ethnic Groups.多基因风险评分对三大主要种族和族裔群体冠心病的预测效用。
Am J Hum Genet. 2020 May 7;106(5):707-716. doi: 10.1016/j.ajhg.2020.04.002.
2
Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease.多基因风险评分与临床风险评分预测冠心病事件的准确性比较。
JAMA. 2020 Feb 18;323(7):627-635. doi: 10.1001/jama.2019.21782.
3
Generalizability of Polygenic Risk Scores for Breast Cancer Among Women With European, African, and Latinx Ancestry.多基因风险评分在具有欧洲、非洲和拉丁裔血统的女性乳腺癌中的可推广性。
JAMA Netw Open. 2021 Aug 2;4(8):e2119084. doi: 10.1001/jamanetworkopen.2021.19084.
4
Development of genome-wide polygenic risk scores for lipid traits and clinical applications for dyslipidemia, subclinical atherosclerosis, and diabetes cardiovascular complications among East Asians.东亚人群脂质特征、血脂异常、亚临床动脉粥样硬化、糖尿病心血管并发症的全基因组多基因风险评分的开发及临床应用。
Genome Med. 2021 Feb 19;13(1):29. doi: 10.1186/s13073-021-00831-z.
5
Polygenic risk scores for the prediction of common cancers in East Asians: A population-based prospective cohort study.基于人群的前瞻性队列研究:东亚常见癌症的多基因风险评分预测。
Elife. 2023 Mar 27;12:e82608. doi: 10.7554/eLife.82608.
6
Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adults.一种经验证的多基因风险评分对中青年长期冠心病风险的预测效用。
Circulation. 2022 Aug 23;146(8):587-596. doi: 10.1161/CIRCULATIONAHA.121.058426. Epub 2022 Jul 26.
7
Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse Genome-Wide Association Study and Population-Specific Optimization.基于具有多种祖先的全基因组关联研究和人群特异性优化的冠心病多祖先多基因风险评分。
Circ Genom Precis Med. 2024 Jun;17(3):e004272. doi: 10.1161/CIRCGEN.123.004272. Epub 2024 Feb 21.
8
Lack of associations of ten candidate coronary heart disease risk genetic variants and subclinical atherosclerosis in four US populations: the Population Architecture using Genomics and Epidemiology (PAGE) study.四项美国人群研究(人口基因组学和流行病学研究 [PAGE])中,十种候选冠心病风险遗传变异与亚临床动脉粥样硬化之间缺乏关联。
Atherosclerosis. 2013 Jun;228(2):390-9. doi: 10.1016/j.atherosclerosis.2013.02.038. Epub 2013 Mar 13.
9
Multi-ancestry polygenic risk scores for venous thromboembolism.多血统多基因静脉血栓栓塞症风险评分。
Hum Mol Genet. 2024 Sep 3;33(18):1584-1591. doi: 10.1093/hmg/ddae097.
10
Polygenic Risk Score for Alzheimer's Disease in Caribbean Hispanics.加勒比海西班牙裔人群阿尔茨海默病的多基因风险评分。
Ann Neurol. 2021 Sep;90(3):366-376. doi: 10.1002/ana.26131. Epub 2021 Jun 17.

引用本文的文献

1
Differential performance of polygenic risk scores for heart disease in Hispanic/Latino subgroups: Findings of the Hispanic Community Health Study/Study of Latinos.西班牙裔/拉丁裔亚组中心脏病多基因风险评分的差异表现:西班牙裔社区健康研究/拉丁裔研究的结果
HGG Adv. 2025 Jul 28;6(4):100486. doi: 10.1016/j.xhgg.2025.100486.
2
Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease: A clinical consensus statement of the ESC Council on Cardiovascular Genomics, the ESC Cardiovascular Risk Collaboration, and the European Association of Preventive Cardiology.用于预测心血管疾病的多基因风险评分的临床效用与应用:欧洲心脏病学会心血管基因组学委员会、欧洲心脏病学会心血管风险协作组及欧洲预防心脏病学协会的临床共识声明
Eur Heart J. 2025 Apr 15;46(15):1372-1383. doi: 10.1093/eurheartj/ehae649.
3
2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.《2025年心脏病和中风统计数据:美国心脏协会关于美国和全球数据的报告》
Circulation. 2025 Feb 25;151(8):e41-e660. doi: 10.1161/CIR.0000000000001303. Epub 2025 Jan 27.
4
Mapping the relative accuracy of cross-ancestry prediction.绘制跨血统预测的相对准确性图谱。
Nat Commun. 2024 Dec 2;15(1):10480. doi: 10.1038/s41467-024-54727-8.
5
Associations of Self-Reported Race, Social Determinants of Health, and Polygenic Risk With Coronary Heart Disease.自述种族、健康社会决定因素和多基因风险与冠心病的关联。
J Am Coll Cardiol. 2024 Nov 26;84(22):2157-2166. doi: 10.1016/j.jacc.2024.06.052.
6
The PRIMED Consortium: Reducing disparities in polygenic risk assessment.PRIMED联盟:减少多基因风险评估中的差异。
Am J Hum Genet. 2024 Dec 5;111(12):2594-2606. doi: 10.1016/j.ajhg.2024.10.010. Epub 2024 Nov 18.
7
Differential prediction performance between Caribbean- and Mainland-subgroups using state-of-the-art polygenic risk scores for coronary heart disease: Findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).使用冠心病的最新多基因风险评分对加勒比裔和大陆裔亚组进行差异预测性能分析:来自西班牙裔社区健康研究/拉丁裔研究(HCHS/SOL)的结果。
medRxiv. 2024 Sep 27:2024.09.25.24313663. doi: 10.1101/2024.09.25.24313663.
8
Polygenic scores and their applications in kidney disease.多基因评分及其在肾脏疾病中的应用。
Nat Rev Nephrol. 2025 Jan;21(1):24-38. doi: 10.1038/s41581-024-00886-2. Epub 2024 Sep 13.
9
Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol.基因预测的脂蛋白(a)与冠状动脉斑块严重程度相关,独立于低密度脂蛋白胆固醇。
Eur J Prev Cardiol. 2025 Jan 27;32(2):116-127. doi: 10.1093/eurjpc/zwae271.
10
Wasm-iCARE: a portable and privacy-preserving web module to build, validate, and apply absolute risk models.Wasm-iCARE:一个用于构建、验证和应用绝对风险模型的便携式且保护隐私的网络模块。
JAMIA Open. 2024 Jun 27;7(2):ooae055. doi: 10.1093/jamiaopen/ooae055. eCollection 2024 Jul.

本文引用的文献

1
iCARE: An R package to build, validate and apply absolute risk models.iCARE:用于构建、验证和应用绝对风险模型的 R 包。
PLoS One. 2020 Feb 5;15(2):e0228198. doi: 10.1371/journal.pone.0228198. eCollection 2020.
2
Using the Data We Have: Improving Diversity in Genomic Research.利用我们现有的数据:改善基因组研究中的多样性。
Am J Hum Genet. 2019 Aug 1;105(2):233-236. doi: 10.1016/j.ajhg.2019.07.008.
3
Genomics of disease risk in globally diverse populations.全球不同人群疾病风险的基因组学。
Nat Rev Genet. 2019 Sep;20(9):520-535. doi: 10.1038/s41576-019-0144-0. Epub 2019 Jun 24.
4
Emerging Concepts in Precision Medicine and Cardiovascular Diseases in Racial and Ethnic Minority Populations.精准医学与少数族裔人群心血管疾病的新观念。
Circ Res. 2019 Jun 21;125(1):7-13. doi: 10.1161/CIRCRESAHA.119.314970. Epub 2019 Jun 20.
5
Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians.验证全基因组多基因风险评分在法裔加拿大人冠状动脉疾病中的作用。
Circ Genom Precis Med. 2019 Jun;12(6):e002481. doi: 10.1161/CIRCGEN.119.002481. Epub 2019 Jun 11.
6
Clinical use of current polygenic risk scores may exacerbate health disparities.现行多基因风险评分的临床应用可能会加剧健康差异。
Nat Genet. 2019 Apr;51(4):584-591. doi: 10.1038/s41588-019-0379-x. Epub 2019 Mar 29.
7
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2019美国心脏病学会/美国心脏协会心血管疾病一级预防指南:美国心脏病学会/美国心脏协会临床实践指南工作组报告
Circulation. 2019 Sep 10;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678. Epub 2019 Mar 17.
8
Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.《2019年心脏病和中风统计数据更新:美国心脏协会报告》
Circulation. 2019 Mar 5;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659.
9
Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction.全基因组测序分析早发性心肌梗死住院患者中单基因和多基因的作用。
Circulation. 2019 Mar 26;139(13):1593-1602. doi: 10.1161/CIRCULATIONAHA.118.035658.
10
Generalizing polygenic risk scores from Europeans to Hispanics/Latinos.将多基因风险评分从欧洲人推广到西班牙裔/拉丁裔。
Genet Epidemiol. 2019 Feb;43(1):50-62. doi: 10.1002/gepi.22166. Epub 2018 Oct 15.

多基因风险评分对三大主要种族和族裔群体冠心病的预测效用。

Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in Three Major Racial and Ethnic Groups.

机构信息

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Am J Hum Genet. 2020 May 7;106(5):707-716. doi: 10.1016/j.ajhg.2020.04.002.

DOI:10.1016/j.ajhg.2020.04.002
PMID:32386537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7212267/
Abstract

Because polygenic risk scores (PRSs) for coronary heart disease (CHD) are derived from mainly European ancestry (EA) cohorts, their validity in African ancestry (AA) and Hispanic ethnicity (HE) individuals is unclear. We investigated associations of "restricted" and genome-wide PRSs with CHD in three major racial and ethnic groups in the U.S. The eMERGE cohort (mean age 48 ± 14 years, 58% female) included 45,645 EA, 7,597 AA, and 2,493 HE individuals. We assessed two restricted PRSs (PRS and PRS; 28 and 50 variants, respectively) and two genome-wide PRSs (PRS and PRS; 1.7 M and 6.6 M variants, respectively) derived from EA cohorts. Over a median follow-up of 11.1 years, 2,652 incident CHD events occurred. Hazard and odds ratios for the association of PRSs with CHD were similar in EA and HE cohorts but lower in AA cohorts. Genome-wide PRSs were more strongly associated with CHD than restricted PRSs were. PRS, the best performing PRS, was associated with CHD in all three cohorts; hazard ratios (95% CI) per 1 SD increase were 1.53 (1.46-1.60), 1.53 (1.23-1.90), and 1.27 (1.13-1.43) for incident CHD in EA, HE, and AA individuals, respectively. The hazard ratios were comparable in the EA and HE cohorts (p = 0.77) but were significantly attenuated in AA individuals (p= 2.9 × 10). These results highlight the potential clinical utility of PRSs for CHD as well as the need to assemble diverse cohorts to generate ancestry- and ethnicity PRSs.

摘要

由于冠心病 (CHD) 的多基因风险评分 (PRSs) 主要来自欧洲血统 (EA) 队列,因此其在非洲血统 (AA) 和西班牙裔 (HE) 个体中的有效性尚不清楚。我们在美国三个主要种族和族裔群体中研究了“受限”和全基因组 PRSs 与 CHD 的关联。eMERGE 队列(平均年龄 48 ± 14 岁,女性占 58%)包括 45645 名 EA、7597 名 AA 和 2493 名 HE 个体。我们评估了来自 EA 队列的两个受限 PRSs(PRS 和 PRS;分别有 28 和 50 个变体)和两个全基因组 PRSs(PRS 和 PRS;分别有 170 万和 660 万个变体)。在中位随访 11.1 年后,发生了 2652 例 CHD 事件。在 EA 和 HE 队列中,PRSs 与 CHD 相关的风险和优势比相似,但在 AA 队列中较低。全基因组 PRSs 与 CHD 的相关性强于受限 PRSs。在所有三个队列中,表现最佳的 PRS PRS 均与 CHD 相关;每增加 1 个 SD,CHD 的风险比(95%CI)分别为 1.53(1.46-1.60)、1.53(1.23-1.90)和 1.27(1.13-1.43)。EA、HE 和 AA 个体的 CHD 发生率分别为 1.53(1.46-1.60)、1.53(1.23-1.90)和 1.27(1.13-1.43)。EA 和 HE 队列中的风险比相当(p=0.77),但在 AA 个体中显著减弱(p=2.9×10)。这些结果突出了 PRSs 对 CHD 的潜在临床应用价值,以及需要组建多样化的队列来生成与血统和种族相关的 PRSs。